339 related articles for article (PubMed ID: 26517538)
1. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
3. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
4. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Johnson TS; Mcgaha T; Munn DH
Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
Muller AJ; Malachowski WP; Prendergast GC
Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
8. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Brochez L; Chevolet I; Kruse V
Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
10. Role of tryptophan metabolism in cancers and therapeutic implications.
Liu XH; Zhai XY
Biochimie; 2021 Mar; 182():131-139. PubMed ID: 33460767
[TBL] [Abstract][Full Text] [Related]
11. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
12. Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.
Ricciuti B; Leonardi GC; Puccetti P; Fallarino F; Bianconi V; Sahebkar A; Baglivo S; Chiari R; Pirro M
Pharmacol Ther; 2019 Apr; 196():105-116. PubMed ID: 30521884
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase in immune suppression and cancer.
Muller AJ; Prendergast GC
Curr Cancer Drug Targets; 2007 Feb; 7(1):31-40. PubMed ID: 17305476
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.
Lin HC; Yang CJ; Kuan YD; Wang WK; Chang WW; Lee CH
Int J Med Sci; 2017; 14(12):1181-1188. PubMed ID: 29104473
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.
Prendergast GC; Smith C; Thomas S; Mandik-Nayak L; Laury-Kleintop L; Metz R; Muller AJ
Cancer Immunol Immunother; 2014 Jul; 63(7):721-35. PubMed ID: 24711084
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ino K
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
[TBL] [Abstract][Full Text] [Related]
17. Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression.
Kuan YD; Lee CH
Oncotarget; 2016 Jan; 7(1):374-85. PubMed ID: 26517244
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.
Di Pucchio T; Danese S; De Cristofaro R; Rutella S
Expert Opin Ther Pat; 2010 Feb; 20(2):229-50. PubMed ID: 20100004
[TBL] [Abstract][Full Text] [Related]
19. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Johnson TS; Munn DH
Immunol Invest; 2012; 41(6-7):765-97. PubMed ID: 23017145
[TBL] [Abstract][Full Text] [Related]
20. Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
Jiang S; Li H; Piao L; Jin Z; Liu J; Chen S; Liu LL; Shao Y; Zhong S; Wu B; Li W; Ren J; Zhang Y; Wang H; Jin R
Aging (Albany NY); 2020 Jun; 12(12):11349-11363. PubMed ID: 32568737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
